Healthcare Global Enterprises Ltd. · NSE:HCG
Healthcare Global Enterprises — Q4 FY2026 Earnings Presentation
29 slides from Healthcare Global Enterprises's earnings presentation, May 19, 2026
Slide 1: Exchange cover letter for investor presentation
May 19, 2026 National Stock Exchange of India Limited, BSE Limited, Compliance Department, Compliance Department, Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai - 400051, Dalal Street, Mumbai - 400001, Maharashtra, India Maharashtra, India Dear Sir/Madam, Subj
Slide 2: Q4 & FY26 Results Presentation
HEALTHCARE GLOBAL ENTERPRISES LIMITED Q 4 & F Y2 6 R e s u l t s P r e s e n ta tio n May 19, 2026
Slide 3: Safe Harbor
Safe Harbor This presentation and its contents are confidential and are not for release, publication or distribution, in whole or in part, directly or indirectly, in or into or from the United States of America, Canada, Australia, Japan or any jurisdiction where such distribution is unlawful. This p
Slide 4: Largest Pan-India Oncology Focused Hospital Chain
Largest Pan-India Oncology Focused Hospital Chain Largest Pan -India Oncology Focused Hospital Chain Our Presence 19 / 10 25 38 Cities / States1 Hospitals2 No. of LINACs3 Jaipur 100 2.6k+ Operation Theatres2 Capacity Beds2 Ahmedabad (2) Indore Ranchi Kolkata Rajkot Baroda Bhavnagar Nagpur Cuttack Na
Slide 5: Proven Profitable Expansion Track Record
Proven Profitable Expansion Track Record Proven Profitable Expansion Track Record FY10 FY15 FY20 FY25 FY26 • Sustained capital deployment with a strategic shift from • Focus on profitable growth • Expanding footprint outside of Karnataka Phase partnership to owned model with prudent capital • Establ
Slide 6: HCG Key Highlights: Q4 and FY26
HCG Key Highlights: Q4 and FY26 HCG Key Highlights: Q4 and FY26 HCG delivered revenue of INR 6,523 Mn in Q4FY26, reflecting ~11% YoY growth; FY26 revenue stood at INR 25,454 Mn, up ~15% YoY, supported by sustained volume growth and steady ARPP improvement • Broad-based growth continued across cluste
Slide 7: Milann Divestment Update
Milann Divestment Update • As part of its strategic objective to sharpen focus on its core oncology and allied healthcare businesses, HCG has agreed to exit non-core fertility business and divest 100% of its stsake in BACC Healthcare Private Limited (operating under the Milann fertility brand), to I
Slide 8: Financial Highlights: Q4FY26
Financial Highlights: Q4FY26 Financial Highlights: Q4FY26 Overall Revenue Adjusted Overall EBITDA1 Adjusted PAT (Post - IND AS)2 Margin (%) 18.3% 19.2% Margin (%) 1.3% 5.2% +11% +17% +363% 1,252 341 6,523 5,852 1,070 74 Q4FY25 Q4FY26 Q4FY25 Q4FY26 Q4FY25 Q4FY26 Revenue (excl. Fertility) Adjusted EBI
Slide 9: Financial Highlights: FY26
Financial Highlights: FY26 Financial Highlights: FY26 Overall Revenue Adjusted EBITDA1 Adjusted PAT (Post - IND AS) 2 ROCE3 Margin (%) 17.8% 18.5% Margin (%) 2.0% 2.2% +15% +87 bps +19% +25% 25,454 557 14% 22,228 4,711 13% 3,963 444 FY25 FY26 FY25 FY26 FY25 FY26 FY25 FY26 Revenue (excl. Fertility) A
Slide 10: FY26 Revenue Mix: By Specialty and Payor
FY26 Revenue Mix: By Specialty and Payor FY26 Revenue Mix: By Specialty and Payor Non Oncology 11% Government OP Onco Medical 33% services Oncology 16% 38% Specialty Payor Mix Mix Medical Value Cash + TPA + Travel Corp Surgical 2% 65% Oncology Radiation 21% Oncology 14% (1) OP services includes OPD
Slide 11: Region-wise Performance Update: South
Region-wise Performance Update: South Region-wise Performance Update: South (# of IP patients) + 13% Revenue Share % + 6% 124,544 109,938 39% Vizag FY26 Overall Gulburga Vijaywada Volumes 29,863 31,723 Hubli Ongole Shimonga Bed share % Q4FY25 Q4FY26 FY25 FY26 Bangalore Chennai 39% + 3% 0.1% FY26 79,
Slide 12: Region-wise Performance Update: West
Region-wise Performance Update: West Region-wise Performance Update: West (# of IP patients) + 9% Revenue Share % 45% + 10% 110,464 120,446 Jaipur FY26 Overall Volumes 27,442 30,249 Indore Rajkot Ahmedabad Baroda Nagpur Bed share % Q4FY25 Q4FY26 FY25 FY26 Bhavnagar Nashik 47% Mumbai + 2% + 5% FY26 9
Slide 13: Region-wise Performance Update: East
Region-wise Performance Update: East Region-wise Performance Update: East (# of IP patients) + 10% Revenue Share % 11% 39,295 43,030 + 13% FY26 Overall Volumes 9,858 11,095 Ranchi 89% Kolkata Bed share % Q4FY25 Q4FY26 FY25 FY26 Cuttack 13% - 4% + 1.4% FY26 65,529 63,018 64,832 65,759 Overall ARPP Q4
Slide 14: Region-wise Performance Update: International and Milann
Region-wise Performance Update: International and Milann Region-wise Performance Update: International and Milann Revenue Share % Revenue (INR Mn) 5% + 71% 740 Kenya FY26 433 International + 39% Nairobi (Kenya) Milann 196 141 Q4FY25 Q4FY26 FY25 FY26 Q4 FY26 Highlights: • Kenya Operations + 5% − Reve
Slide 15: Capital Expenditure and Net Debt
Capital Expenditure and Net Debt Capital Expenditure and Net Debt Capital Expenditure (INR Mn) Net Debt (INR Mn) Regions FY25 FY26 Net Debt Items 31st Mar 2026 31st Mar 2025 Borrowings(1) 8,817 9,814 South 1,221 1,804 Less: Cash & Cash Equivalents(2) (5,430) (3,497) West 802 794 Net Debt 3,387 6,317
Slide 16: Net Debt (Pre Ind-AS)
Net Debt (Pre Ind -AS) HCG continues to demonstrate healthy cash conversion at 75% EBITDA to CFO; Balance sheet has further de-levered to ~1.43x following the rights issue and payment of Vizag acquisition, creating headroom to further invest in growth 2.27x 0.98x Net Debt 3,471 • EBITDA to CFO of ~7
Slide 17: North Bangalore Update
North Bangalore Update North Bangalore Launch • 1st in Bangalore market to offer MR-LINAC technology, creating a strong clinical and technology-led differentiation • Spanning 1.5 lakh sq. ft. and strategically positioned to serve the rapidly growing northern corridor with catchment population of 2+
Slide 18: Hospital Utilization and Growth Potential in Existing Centres
Hospital Utilization and Growth Potential in Existing Centres Existing network continue to witness healthy ramp up in utilization, with significant headroom for sustained future growth Revenue 9,950 11,330 2,830 25,454 (INRmn) FY26 Hospital Utilization (%) 68% 57% 58% 50% South West East HCG Overall
Slide 19: Path to Improve Profitability and Return on Capital
Path to Improve Profitability and Return on Capital • Continued movement of centres into higher revenue buckets driving structural improvement in HCG’s EBITDA margins and ROCE • The growing INR 50–100Mn cohort, with infrastructure already built out, provides a strong foundation for future margin exp
Slide 20: Q4 & FY26 Consolidated Profit & Loss Account
Q4 FY26 Consolidated Profit Loss Account Q4 & FY26 Consolidated Profit & Loss Account Profit and Loss (INR in Mn.) Q4FY26 Q4FY25 Y-o-Y FY26 FY25 Y-o-Y Revenues from Operations 6,502.9 5,834.3 25,384.3 22,181.4 Income from Govt. Grant 20.4 17.3 69.8 47.1 Total Revenue from Operations 6,523.3 5,851.6
Slide 21: Consolidated Balance Sheet
Consolidated Balance Sheet Consolidated Balance Sheet Balance Sheet – Equities & Liabilities (INR in Mn.) Mar-26 Mar-25 Balance Sheet – Assets (INR in Mn.) Mar-26 Mar-25 Equity share capital 1,493.0 1,394.2 Non-Current Assets Other equity 11,826.7 7,830.3 Property, Plant And Equipment 13,927.9 12,68
Slide 22: Cashflow Statement
Cashflow Statement Cashflow Statement Cashflow Statement (INR in Mn.) Mar-26 Mar-25 Net Profit Before Tax 269.1 569.6 Adjustments For: Non - Cash Items / Other Investment Or Financial Items 3,945.6 3,685.2 Operating Profit Before Working Capital Changes 4,214.7 4,254.9 Changes in Working Capital (42
Slide 23: HCG: India's Leading Oncology Platform
HCG: India’s Leading Oncology Platform 22 www.hcgoncology.com www. h c g o n c o l o g y. c o m
Slide 24: A Unique Oncology Platform Redefining Comprehensive Cancer Care Treatment
A Unique Oncology Platform Redefining Comprehensive Cancer Care Treatment A Unique Oncology Platform Redefining Comprehensive Cancer Care Treatment Largest oncology-focused hospital chain Best-in-class medical talent pool with with a pan-India network industry-leading retention Deepest network acros
Slide 25: HCG is Positioned as the 'Destination for Cancer Care'
HCG is Positioned as the ‘Destination for Cancer Care’ with Superior Clinical and Non‐clinical Expertise… HCG is Positioned as the ‘Destination for Cancer Care’ with Superior Clinical and Non -clinical Expertise… Diagnostics Treatment Post Care Genomics and Digital PET Preventive Medical Oncology Ra
Slide 26: Including Cutting-edge Technology
…including Cutting -edge Technology TRACK RECORD OF BEING 1st TO LAUNCH State-of-the-art Equipment in each modality ADVANCED TECHNOLOGY IN INDIA DIAGNOSTICS Total PET CTs : 19 2026 MR-LINAC1 AI- based 2022 Digital PET Digital CT Automated Digital Skyra Tesla 3T Molecular / RIS PACS Pathology Breast
Slide 27: Strategic Priorities
Strategic Priorities Clinical Outcomes, Growth and Profitability A B C D Optimize Existing Improve Network Enhance Patient Invest in Growth Network Efficiency Experience 1. Build best-in-class talent → 1. Brownfield expansion across 1. Undertake prudent cost 1. Invest in upgrading existing improve c
Slide 28: About Us
CIN: L15200KA1998PLC023489 About Us: HealthCare Global Enterprises Ltd. For updates and specific queries, please visit www.hcgoncology.com or contact: (HCG), headquartered in Bengaluru, is the largest provider of cancer care in India. Through its network of 25 hospitals across India and Africa, Heal
Slide 29: Thank You
THANK YOU www.hcgoncology.com www. h c g o n c o l o g y. c o m
HealthCare Global Enterprises — Q4 FY2026 Earnings Presentation on 6ix